Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review

Monika Sugalska, Anna Tomik, Sergiusz Jóźwiak and Bożena Werner
Additional contact information
Monika Sugalska: Department of Pediatric Neurology, Medical University of Warsaw, 02-091 Warsaw, Poland
Anna Tomik: Department of Pediatric Cardiology, Medical University of Warsaw, 02-091 Warsaw, Poland
Sergiusz Jóźwiak: Department of Pediatric Neurology, Medical University of Warsaw, 02-091 Warsaw, Poland
Bożena Werner: Department of Pediatric Cardiology, Medical University of Warsaw, 02-091 Warsaw, Poland

IJERPH, 2021, vol. 18, issue 9, 1-22

Abstract: Background: Cardiac rhabdomyomas (CRs) are the earliest sign of tuberous sclerosis complex (TSC). Most of them spontaneously regress after birth. However, multiple and/or large tumors may result in heart failure or cardiac arrhythmia. Recently, the attempts to treat CRs with mTOR inhibitors (mTORi) have been undertaken. We reviewed the current data regarding the effectiveness and safety of mTORi in the treatment of CRs in children with TSC. Methods: The review was conducted according to the PRISMA guidelines. Medline, Embase, Cochrane library, and ClinicalTrial.gov databases were searched for original, full-text articles reporting the use of mTORi (everolimus or sirolimus) in the treatment of CRs in children with TSC. Results: Thirty articles describing 41 patients were identified (mostly case reports, no randomized or large cohort studies). Thirty-three children (80.5%) had symptomatic CRs and mTORi therapy resulted in clinical improvement in 30 of them (90.9%). CRs size reduction was reported in 95.1%. Some CRs regrew after mTORi withdrawal but usually without clinical symptoms recurrence. The observed side effects were mostly mild. Conclusions: mTORi may be considered as a temporary and safe treatment for symptomatic CRs in children with TSC, especially in high-risk or inoperable tumors. However, high-quality, randomized trials are still lacking.

Keywords: tuberous sclerosis complex; everolimus; sirolimus; mTOR inhibitor; cardiac rhabdomyoma; heart; tumor; children (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/9/4907/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/9/4907/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:9:p:4907-:d:548897

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().